医学
止血
重组因子VIIa
凝结
凝血因子
围手术期
抗凝治疗
血小板
外科
重症监护医学
免疫学
内科学
作者
Harold R. Roberts,Dougald M. Monroe,Miguel Antonio Escobar,Richard B. Weiskopf
出处
期刊:Anesthesiology
[Lippincott Williams & Wilkins]
日期:2004-02-25
卷期号:100 (3): 722-730
被引量:157
标识
DOI:10.1097/00000542-200403000-00036
摘要
The revised model of coagulation has implications for therapy of both hemorrhagic and thrombotic disorders. Of particular interest to anesthesiologists is the management of clotting abnormalities before, during, and after surgery. Most hereditary and acquired coagulation factor deficiencies can be managed by specific replacement therapy using clotting factor concentrates. Specific guidelines have also been developed for perioperative management of patients using anticoagulant agents that inhibit platelet or coagulation factor functions. Finally, recombinant factor VIIa has been used off-label as a hemostatic agent in some surgical situations associated with excessive bleeding that is not responsive to conventional therapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI